DiaSorin Molecular has announced the expansion of its menu of molecular reagents with the introduction of a Pneumocystis jirovecii primer pair for use in laboratory-developed molecular tests. This analyte-specific reagent (ASR) can be used for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers. This is DiaSorin’s first fungal infectious disease target.
The new primer pair joins DiaSorin’s menu of more than 60 molecular reagents that can be used to detect bacterial and viral targets in addition to human genetic mutations. The primer pairs are classified as analyte-specific reagents, which are used by high-complexity laboratories to develop their own lab-developed tests (LDTs).
“This new primer pair is the result of our ongoing work to develop and deliver a robust menu of molecular products,” said Michelle Tabb, vice president of research and development for DiaSorin Molecular. “With greater access to commercially developed molecular reagents, diagnostic labs are better able to customize tests that meet their unique patient needs.”
This test quantifies BCR-ABL the gene fusion that causes CML, in the blood. Though no criteria been established to determine when therapy can be stopped, the detection of low BCR-ABL levels may help physicians provide their patients with the best possible treatment.
Radiometer’s AQT90 FLEX analysers have been used in a successful trial to asses D-dimer point-of-care testing (POCT) for suspected lower limb deep vein thrombosis (DVT), at the Great Western Hospitals NHS Foundation Trust.